
Matthew N Meriggioli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1085777/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. Journal of Neuromuscular Diseases, 2017, 4, 169-173.	2.6	33
2	TDPâ€43 Proteinopathy: Aggregation and Propagation in the Pathogenesis of Amyotrophic Lateral Sclerosis. Movement Disorders, 2016, 31, 1139-1139.	3.9	4
3	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
4	Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics, 2016, 13, 118-131.	4.4	53
5	The Clinical Spectrum of Necrotizing Autoimmune Myopathy. JAMA Neurology, 2015, 72, 977.	9.0	1
6	Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. Journal of Autoimmunity, 2014, 52, 64-73.	6.5	45
7	Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurology, The, 2009, 8, 475-490.	10.2	775
8	Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. Journal of Immunology, 2006, 177, 5296-5306.	0.8	72
9	Myasthenia Gravis: Diagnosis. Seminars in Neurology, 2004, 24, 31-39.	1.4	64